Discovery, mechanisms of action and combination therapy of artemisinin

Liwang Cui, Xin Zhuan Su

Research output: Contribution to journalReview article

167 Citations (Scopus)

Abstract

Despite great international efforts, malaria still inflicts an enormous toll on human lives, especially in Africa. Throughout history, antimalarial medicines have been one of the most powerful tools in malaria control. However, the acquisition and spread of parasite strains that are resistant to multiple antimalarial drugs have become one of the greatest challenges to malaria treatment, and are associated with the increase in morbidity and mortality in many malaria-endemic countries. To deal with this grave situation, artemisinin-based combinatory therapies (ACTs) have been introduced and widely deployed in malarious regions. Artemisinin is a new class of antimalarial compounds discovered by Chinese scientists from the sweet wormwood Artemisia annua. The potential development of resistance to artemisinins by Plasmodium falciparum threatens the usable lifespan of ACTs, and therefore is a subject of close surveillance and extensive research. Studies at the Thai-Cambodian border, a historical epicenter of multidrug resistance, have detected reduced susceptibility to artemisinins as manifested by prolonged parasite-clearance times, raising considerable concerns on resistance development. Despite this significance, there is still controversy on the mode of action of artemisinins. Although a number of potential cellular targets of artemisinins have been proposed, they remain to be verified experimentally. Here, we review the history of artemisinin discovery, discuss the mode of action and potential drug targets, and present strategies to elucidate resistance mechanisms.

Original languageEnglish (US)
Pages (from-to)999-1013
Number of pages15
JournalExpert Review of Anti-Infective Therapy
Volume7
Issue number8
DOIs
StatePublished - Oct 1 2009

Fingerprint

Artemisinins
Malaria
Antimalarials
Artemisia annua
Parasites
History
Multiple Drug Resistance
Therapeutics
Plasmodium falciparum
Action Potentials
Morbidity
Mortality
artemisinine
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

Cui, Liwang ; Su, Xin Zhuan. / Discovery, mechanisms of action and combination therapy of artemisinin. In: Expert Review of Anti-Infective Therapy. 2009 ; Vol. 7, No. 8. pp. 999-1013.
@article{1fb0c245af874eb597255767cb9c4850,
title = "Discovery, mechanisms of action and combination therapy of artemisinin",
abstract = "Despite great international efforts, malaria still inflicts an enormous toll on human lives, especially in Africa. Throughout history, antimalarial medicines have been one of the most powerful tools in malaria control. However, the acquisition and spread of parasite strains that are resistant to multiple antimalarial drugs have become one of the greatest challenges to malaria treatment, and are associated with the increase in morbidity and mortality in many malaria-endemic countries. To deal with this grave situation, artemisinin-based combinatory therapies (ACTs) have been introduced and widely deployed in malarious regions. Artemisinin is a new class of antimalarial compounds discovered by Chinese scientists from the sweet wormwood Artemisia annua. The potential development of resistance to artemisinins by Plasmodium falciparum threatens the usable lifespan of ACTs, and therefore is a subject of close surveillance and extensive research. Studies at the Thai-Cambodian border, a historical epicenter of multidrug resistance, have detected reduced susceptibility to artemisinins as manifested by prolonged parasite-clearance times, raising considerable concerns on resistance development. Despite this significance, there is still controversy on the mode of action of artemisinins. Although a number of potential cellular targets of artemisinins have been proposed, they remain to be verified experimentally. Here, we review the history of artemisinin discovery, discuss the mode of action and potential drug targets, and present strategies to elucidate resistance mechanisms.",
author = "Liwang Cui and Su, {Xin Zhuan}",
year = "2009",
month = "10",
day = "1",
doi = "10.1586/ERI.09.68",
language = "English (US)",
volume = "7",
pages = "999--1013",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "8",

}

Discovery, mechanisms of action and combination therapy of artemisinin. / Cui, Liwang; Su, Xin Zhuan.

In: Expert Review of Anti-Infective Therapy, Vol. 7, No. 8, 01.10.2009, p. 999-1013.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Discovery, mechanisms of action and combination therapy of artemisinin

AU - Cui, Liwang

AU - Su, Xin Zhuan

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Despite great international efforts, malaria still inflicts an enormous toll on human lives, especially in Africa. Throughout history, antimalarial medicines have been one of the most powerful tools in malaria control. However, the acquisition and spread of parasite strains that are resistant to multiple antimalarial drugs have become one of the greatest challenges to malaria treatment, and are associated with the increase in morbidity and mortality in many malaria-endemic countries. To deal with this grave situation, artemisinin-based combinatory therapies (ACTs) have been introduced and widely deployed in malarious regions. Artemisinin is a new class of antimalarial compounds discovered by Chinese scientists from the sweet wormwood Artemisia annua. The potential development of resistance to artemisinins by Plasmodium falciparum threatens the usable lifespan of ACTs, and therefore is a subject of close surveillance and extensive research. Studies at the Thai-Cambodian border, a historical epicenter of multidrug resistance, have detected reduced susceptibility to artemisinins as manifested by prolonged parasite-clearance times, raising considerable concerns on resistance development. Despite this significance, there is still controversy on the mode of action of artemisinins. Although a number of potential cellular targets of artemisinins have been proposed, they remain to be verified experimentally. Here, we review the history of artemisinin discovery, discuss the mode of action and potential drug targets, and present strategies to elucidate resistance mechanisms.

AB - Despite great international efforts, malaria still inflicts an enormous toll on human lives, especially in Africa. Throughout history, antimalarial medicines have been one of the most powerful tools in malaria control. However, the acquisition and spread of parasite strains that are resistant to multiple antimalarial drugs have become one of the greatest challenges to malaria treatment, and are associated with the increase in morbidity and mortality in many malaria-endemic countries. To deal with this grave situation, artemisinin-based combinatory therapies (ACTs) have been introduced and widely deployed in malarious regions. Artemisinin is a new class of antimalarial compounds discovered by Chinese scientists from the sweet wormwood Artemisia annua. The potential development of resistance to artemisinins by Plasmodium falciparum threatens the usable lifespan of ACTs, and therefore is a subject of close surveillance and extensive research. Studies at the Thai-Cambodian border, a historical epicenter of multidrug resistance, have detected reduced susceptibility to artemisinins as manifested by prolonged parasite-clearance times, raising considerable concerns on resistance development. Despite this significance, there is still controversy on the mode of action of artemisinins. Although a number of potential cellular targets of artemisinins have been proposed, they remain to be verified experimentally. Here, we review the history of artemisinin discovery, discuss the mode of action and potential drug targets, and present strategies to elucidate resistance mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=70350616263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350616263&partnerID=8YFLogxK

U2 - 10.1586/ERI.09.68

DO - 10.1586/ERI.09.68

M3 - Review article

C2 - 19803708

AN - SCOPUS:70350616263

VL - 7

SP - 999

EP - 1013

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 8

ER -